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The activity of the human oncogene and
chromatin remodeler ALC1/CHD1L is
strictly regulated by PARP1 activation.
Singh et al. reveal how oligomers of ADP-
ribose trigger the activation of ALC1 from
an auto-inhibited state and identify
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DNA damage triggers chromatin remodeling by
mechanisms that are poorly understood. The
oncogene and chromatin remodeler ALC1/CHD1L
massively decompacts chromatin in vivo yet is
inactive prior to DNA-damage-mediated PARP1 in-
duction. We show that the interaction of the ALC1
macrodomain with the ATPase module mediates
auto-inhibition. PARP1 activation suppresses this
inhibitory interaction. Crucially, release from auto-
inhibition requires a poly-ADP-ribose (PAR) binding
macrodomain. We identify tri-ADP-ribose as a
potent PAR-mimic and synthetic allosteric effector
that abrogates ATPase-macrodomain interactions,
promotes an ungated conformation, and activates
the remodeler’s ATPase. ALC1 fragments lacking
the regulatory macrodomain relax chromatin in vivo
without requiring PARP1 activation. Further, the
ATPase restricts the macrodomain’s interaction
with PARP1 under non-DNA damage conditions.
Somatic cancer mutants disrupt ALC1’s auto-
inhibition and activate chromatin remodeling.
Our data show that the NAD+-metabolite and
nucleic acid PAR triggers ALC1 to drive chromatin
relaxation. Modular allostery in this oncogene
tightly controls its robust, DNA-damage-dependent
activation.860 Molecular Cell 68, 860–871, December 7, 2017 ª 2017 Elsevier IINTRODUCTION
Chromatin structure safeguards the integrity of our genome.
Distinct families of chromatin remodeling enzymes establish
and maintain chromatin structure, for example by facilitating
the binding of transcription factors to functional DNA elements
or assisting the repair machinery uponDNA damage. Key to con-
trolling the activity of these ATPases are chromatin targeting
mechanisms and regulatory interactions (Dann et al., 2017).
Such mechanisms help ensure that remodelers are only active
where and when needed. While the mechanisms through which
the Chd1 and ISWI remodelers are regulated by nucleosomes
have been explored (Clapier and Cairns, 2012; Hauk et al.,
2010; Ludwigsen et al., 2017; Yan et al., 2016), less is known
about how DNA damage triggers the activity of remodelers
such as the PARP1-dependent ALC1 (Ahel et al., 2009; Gott-
schalk et al., 2012; 2009), which massively decompacts
chromatin upon DNA damage (Movie S1; Sellou et al., 2016).
Considering ALC1’s validated roles as an oncogene (ALC1
is amplified in several cancers and promotes metastases, prolif-
eration, and pluripotency; Chen et al., 2010; Jiang et al., 2015;
Kulkarni et al., 2013; Ma et al., 2008), understanding how PAR
triggers ALC1 activity would advance our molecular understand-
ing of how DNA damage impacts our genome, shed light on how
a NAD+ metabolite and nucleic acid triggers the activation of an
oncogene, and reveal approaches that might allow us to target
ALC1 therapeutically.
Single-strand DNA breaks rapidly induce the activity of
PARP1, PARP2, and PARP3, enzymes that use NAD+ to ADP-ri-
bosylate chromatin and other cellular targets (Carter-O’Connellnc.
et al., 2016; Gibson et al., 2016; Grundy et al., 2016). The clinical
promise of PARP1 inhibitors in cancer therapy (Lord and Ash-
worth, 2017) and the identification of domains that recognize
ADP-ribosylated proteins, including ADP-ribose binding macro-
domains (Karras et al., 2005; Kustatscher et al., 2005), has
rekindled interest in NAD+ signaling (Cambronne et al., 2016;
Kim et al., 2004; Petesch and Lis, 2012; Tulin and Spradling,
2003). While cellular mono-ADP-ribosylation, catalyzed by
related PARP enzymes, is thought to act as a reversible, regula-
tory post-translational modification (PTM) (Jankevicius et al.,
2013; Rosenthal et al., 2013; Sharifi et al., 2013), the tightly regu-
lated synthesis of PAR by PARP1 and PARP2 profoundly alters
nuclear organization and cellular homeostasis (Altmeyer et al.,
2015; Asher et al., 2010; Bai et al., 2011a; 2011b; Wright
et al., 2016).
PAR is a nucleic acid with important roles in the stress
response to DNA damage. It is as an abundant, transient poly-
meric anion that can promote phase separation (Altmeyer
et al., 2015; Asher et al., 2010; Bai et al., 2011a, 2011b; Wright
et al., 2016). Sites of high PARP1 activity in vivo recruit ATP-
dependent remodelers, including ALC1 (Amplified in Liver
Cancer 1; also known as CHD1L), CHD2, CHD4, SMARCA5/
SNF2H, and Drosophila Mi-2 (Chou et al., 2010; Murawska
et al., 2011; Polo et al., 2010; Smeenk et al., 2013). Remodelers
such as ALC1 and CHD2 mediate chromatin relaxation through
unknown mechanisms at the site of DNA damage (Luijsterburg
et al., 2016; Sellou et al., 2016). These are some of the earliest,
PARP-dependent changes in chromatin structure upon DNA
damage (Kruhlak et al., 2006; Poirier et al., 1982; Strickfaden
et al., 2016).
Others and we have shown that ALC1 recruits to DNA damage
sites upon PARP1 activation. Recruitment and PAR binding
requires its C-terminal, PAR-binding macrodomain module
(Ahel et al., 2009; Gottschalk et al., 2009, 2012; Jiang et al.,
2015). Interestingly, its ATPase and nucleosome-remodeling
activities depend on PARP1 activation. In vitro assays reveal
that PARylated PARP1 promotes ALC1-dependent nucleosome
sliding (Ahel et al., 2009; Gottschalk et al., 2009, 2012). Key to
ALC1’s activity is the ability of its macrodomain to recognize
PARylated PARP1. However, what keeps ALC1 inactive prior
to PARP1 activation and how the nuclear metabolite and nucleic
acid PAR triggers ALC1 activation are not known.
RESULTS
Modular Auto-Inhibition in the Remodeler ALC1
We set out to investigate what suppresses ALC1 remodeler
activity when PARP1 is inactive. Unlikemost remodelers, endog-
enous ALC1 does not purify as a multi-subunit complex, and its
remodeling activity can be efficiently reconstituted in vitro using
recombinant protein and DNA, together with PARP1 and NAD+
(Ahel et al., 2009; Gottschalk et al., 2009, 2012). The enzyme
consists of a two-lobed catalytic Snf2-like ATPase domain with
homology to ATP-dependent DExx-box helicase (ATPase, Fig-
ure 1A), which is connected through a linker region of unknown
function to a C-terminal macrodomain (macro), which mediates
PARP1 activity-dependent chromatin-targeting (Ahel et al.,
2009; Gottschalk et al., 2009, 2012).To establish whether the ALC1 ATPase domain and macro-
domain interact, we generated an ATPase fragment (residues
31–615; ‘‘ATPase module’’) and a fragment containing both
linker and C-terminal macrodomain (residues 616–878;
‘‘macro module’’) (Figure 1A). The domain boundaries were
identified using limited proteolysis (Figure S1). The recombi-
nant ATPase and macrodomain modules can be expressed
individually in E. coli and purified to homogeneity. Multiple
lines of biochemical evidence show that the two modules
form a stable complex. The two fragments interact with each
other in pull-down assays (Figure 1B). Size-exclusion chroma-
tography assays reveal the formation of a stoichiometric 1:1
complex (Figure 1C), which elutes with a molecular size
(138 kDa) close to that of the (near) full-length ALC1
construct (residues 31—878; eluting at 131 kDa; Figure 1D).
Thus, ALC1 behaves as a monomer. To determine the affinity
of the two ALC1 modules for each other, we employed
isothermal titration calorimetry (ITC) assays, which reveal an
equilibrium dissociation constant of 96 ± 22 nM (Figure 1E).
These results indicate that the ATPase and macrodomain
modules of the ALC1 remodeler engage through a tight,
intra-molecular interaction.
To test whether this interaction is observed in living cells, we
used fluorescence-two-hybrid (F2H) analysis (Zolghadr et al.,
2012). Tethering of a fluorescent mCherry-LacI-ALC1 macrodo-
main bait to an integrated LacO array in U2OS cells enriches the
eYFP-tagged ALC1 ATPase prey (Figures 1F and S1), while un-
related macrodomains do not recognize the ALC1 ATPase. We
conclude that in the absence of exogenous DNA damage (i.e.,
when PARP1 has not been induced), the ALC1 modules specif-
ically interact with each other. To rule out the possibility that
ALC1 may form dimers, trimers, or other, higher-order com-
plexes through intermolecular domain swapping, we conducted
co-immunoprecipitation and F2H assays with full-length ALC1
(Figure S2). Both assays indicate that ALC1 is a monomer in vivo
(compared to positive controls). Our data suggest that the C-ter-
minal macrodomain of ALC1 packs against one or both of its
ATPase lobes in the context of the full-length ALC1 protein, hint-
ing at an intramolecular ‘‘gating’’ function of the ALC1 macrodo-
main, as described for the unrelated chromodomain of yCHD1
and the NTR domain of ISWI (Hauk et al., 2010; Ludwigsen
et al., 2017).
To probe the domain topology of ALC1, we used MS cross-
linking. We mapped multiple crosslinks within each of the two
ALC1 modules, including between the flexible linker region and
the canonical ATPase and macrodomain folds (Figure S1;
Table S1). The cross-linking pattern complements well the
domain boundaries identified by limited proteolysis (Figure S1).
The MS-based crosslinks indicate that the ALC1 hinge contacts
the macrodomain and ATPase, confirming our limited proteoly-
sis data. Together, crosslinking and limited proteolysis (Fig-
ure S1) hint at a compact arrangement of the ALC1 ATPase
and macrodomain modules with respect to each other, consis-
tent with a ‘‘gated’’ structure, which may restrict DNA access
to the ATPase motor. We conclude that in the absence of acti-
vated PARP1, intramolecular interactions between themacrodo-
main and ATPase modules establish an auto-inhibited ALC1







Figure 1. The ALC1 Macrodomain Interacts
with the ATPase Module in the Enzyme’s
Inhibited State
(A) The ALC1 oncogene is composed of two primary
modules: an N-terminal Snf2-like ATPase module
(residues 31–615) and a C-terminal macrodomain
module (616–878). The boundaries were defined
using limited proteolysis (Figure S1). NLS, nuclear
localization signal.
(B) SDS-PAGE of a V5-based pull-down with re-
combinant, purified ALC1macrodomain and ATPase
module. The asterisk denotes anti-V5 IgG heavy and
light chains.
(C) Size exclusion chromatography (SEC) of re-
combinant, purified ALC1 macrodomain (residues
636–878,orange), ATPase domain (residues 31–615,
cyan), and in vitro-reconstituted complex (black),
plus SDS-PAGE of the eluted fractions.
(D) Comparison of the elution profiles by gel filtration
of the reconstituted ALC1 ATPase–macrodomain
complex with purified, near-full-length ALC1 (resi-
dues 31–878).
(E) Isothermal titration calorimetry (ITC) assays show
that ALC1’s two modules bind each other in a high-
affinity, exothermic reaction and with 1:1 stoichiom-
etry (N = 0.87 ± 0.05).
(F) Fluorescence-two-hybrid (F2H) analysis in live
cells (Zolghadr et al., 2012) reveals that ALC1’s
ATPase (eYFP-ATPase; prey) readily enriches on a
LacO-array tethered mCherry-LacI-macrodomain
(bait). Example image (top images), quantitation
(n = 20), and comparison with unrelated macro-
domains reveal a specific ALC1 ATPase and ALC1
macrodomain interaction (bottom chart). Error bar
represents the SEM, n R 20.
See also Figures S1 and S2 and Table S1.PARP1 Activation Disrupts the Auto-Inhibited State
ALC1 rapidly recruits to DNA damage sites and massively
decompacts chromatin in response to PARP1 activation (Ahel
et al., 2009; Gottschalk et al., 2009; Sellou et al., 2016). These
activities require a functional, PAR-binding ALC1 macrodo-
main. We hypothesized that PAR binding to ALC1 may promote
an active conformation of ALC1. To determine whether the
activation of PARP1 in living cells alters the modular, intra-mo-
lecular interactions within ALC1, we used the F2H assay to
measure the interaction of the ALC1 ATPase module with the
macrodomain prior to and following UV-laser induced PARP1
activation. DNA damage leads to a time-dependent decrease
of ALC1 ATPase prey from the tethered ALC1 macrodomain
(Figure 2A; Movie S2). We conclude that PARP1 activation
leads to the loss of interaction between the two ALC1 modules.
H2O2-induced DNA damage also leads to a loss of interaction862 Molecular Cell 68, 860–871, December 7, 2017(Figure S2), and the site of PARP1 acti-
vation and ALC1 ATPase–macrodomain
dissociation do not need to overlap, since
FRAP assays indicate high turnover of our
fusion proteins (Figure S2). Importantly, a
G750E mutant within the macrodomain,
which disrupts binding of the pyrophos-
phate of ADP-ribose in canonical macro-domains (Kustatscher et al., 2005), retains its binding with the
ATPase module, even upon PARP1 induction (Figure S2).
These data reveal that the interaction between the two ALC1
modules is regulated by PARP1 activation in vivo. PAR binding
to the macrodomain is coupled to the loss of interaction with
the ATPase module, consistent with a direct, allosteric regula-
tion of ALC1 by PAR.
Next, we sought to determine the minimal ALC1 ligand that is
necessary and sufficient to trigger ATPase–macrodomain disso-
ciation and PAR-mediated ALC1 activation. We tested the effect
of PARP1 activation in vitro on the interaction between ALC1
ATPase and macrodomain. Addition of NAD+ to a pull-down
containing PARP1, DNA, and the two ALC1 modules disrupts
ALC1 ATPase–macrodomain interaction (Figure 2B, lanes
4 and 5). Addition of PARP1 inhibitors suppresses the disruptive
effect of PARylation on ATPase–macrodomain interaction (lanes
A
B
Figure 2. Acute DNA Damage and PARP1
Activation Trigger the Release of the ALC1
ATPase Module from a Tethered ALC1
Macrodomain
(A) The LacO-tethered LacI-ALC1 macrodomain
module (bait) enriches ALC1’s ATPase (prey) in the
absence of exogenousDNA damage (left, compare
white dot within the top and bottom yellow
squares). Upon targeted and localized UV-laser-
induced DNA damage (red square), the activation
of the endogenous PARP1 enzyme leads to the
dissociation of ALC1’s ATPase module from the
chromatin-tethered macrodomain (next panels).
Upon DNA damage, the ALC1 macrodomain bait
enriches at the DNA damage site, as expected
from the local synthesis of its ligand poly-ADP-
ribose, PAR (Ahel et al., 2009; Gottschalk et al.,
2009). Both ALC1 recruitment (Ahel et al., 2009;
Gottschalk et al., 2009) and the disruption of
ATPase–macrodomain interactions require PARP1
activity.
(B) In vitro pull-down assays with V5-tagged ALC1
macrodomain reconstitute the PARP1 activity- and
PAR-dependent dissociation of the modular
ATPase–macrodomain interaction. Shown are
lanes 1 and 2 with untagged ATPase and V5-tag-
ged macro modules alone, respectively. Disruption
of the ATPase–macrodomain complex requires
PARP1, DNA and cofactor NAD+ (lanes 3–5).
Addition of small-molecule PARP1 inhibitors
suppresses the PARP1 activity-dependent disso-
ciation (lanes 6 and 7). The ALC1 ATPase–macro-
domain complex is wholly disrupted by addition of
pure PAR to the reaction, while a macrodomain
point mutant (G750E), which alters ADP-ribose binding within its canonical ADP-ribose binding pocket, largely retains binding to the ALC1 ATPase module
(lanes 11 and 12). In contrast to PAR, monomeric ADP-ribose fails to disrupt ATPase–macrodomain interactions for both wild-type and G750E mutant ALC1
macrodomain module (lanes 8–10). The asterisk denotes anti-V5 IgG heavy and light chains.
See also Figure S2.6 and 7 versus lane 5). As expected, a point mutant within the
ADP-ribose binding pocket of ALC1 (G750E) retains ATPase
interaction (lane 8). Consistent with our in vivo observations (Fig-
ure S2), the interaction of the G750E macrodomain mutant with
the ALC1 ATPase resists the addition of PAR (Figure 2B, lane 11).
In sharp contrast, the wild-type macrodomain dissociates from
the ATPase module upon PAR incubation (Figure 2B, lane 12).
Thus, PAR in vitro is sufficient to dissociate the macrodomain
of ALC1 from its ATPase. Further, dissociation requires a func-
tional, PAR-binding macrodomain. Thus, PAR allosterically
switches ALC1.
Synthetic Tri-ADP-Ribose Is a Nanomolar Effector of
ALC1 Allostery
Macrodomains generally show high affinity for monomeric
ADP-ribose (Karras et al., 2005; Kustatscher et al., 2005). Our
ATPase–macrodomain competition assay, however, reveals
thatmono-ADP-ribose does not abrogate ALC1 ATPase–macro-
domain interactions (Figure 2B, lane 10 versus lane 12), even
when added in 100-fold molar excess, while PAR readily
dissociates the complex. Consistently, ITC fails to detect an
interaction between mono-ADP-ribose and the wild-type ALC1
macrodomain (Figure 3A; Table S2). Although key residues
within the canonical ADP-ribose binding pocket of macrodo-mains are conserved in the PAR-binding ALC1 macrodomain,
our data reveal that mono-ADP-ribose is not an ALC1 ligand.
We hypothesized that binding of PAR to ALC1 may require
multiple ADP-ribose units. Interestingly, a PAR footprinting
assay revealed that ALC1 protects oligomers of 3 to >20
ADP-ribose units in length (Gottschalk et al., 2012). We therefore
synthesized dimeric and trimeric forms of ADP-ribose (Kiste-
maker et al., 2015) and tested their binding to the ALC1 macro-
domain. Remarkably, the ALC1 macrodomain binds di-ADP-
ribose with a KD = 3.7 mM and tri-ADP-ribose with nanomolar
affinity (KD = 10.6 nM; Figure 3A; Table S2). Extending ADP-
ribose from monomer to trimer thus turns the NAD+ metabolite
into a high-affinity ligand. In sharp contrast to ALC1, the macro-
domain of human histonemacroH2A.1.1 recognizesmono-ADP-
ribose and di-ADP-ribose with the same KD (Figure S3). This
indicates that ALC1 contains a NAD+-metabolite binding surface
that recognizes multiple features within tri-ADP-ribose. High-
lighting the high affinity of the ALC1 macrodomain for tri-ADP-
ribose, thermal shift assays reveal an 10C stabilization of the
macrodomain by tri-ADP-ribose (Figure S3). To probe the selec-
tivity of ALC1 toward related nucleotides, we conducted ITCwith
tri-adenylate RNA, tri-adenylate ssDNA, and penta-adenylate
ssDNA. All fail to bind ALC1 (data not shown). Further, ITC and




Figure 3. Tri-ADP-Ribose Is a Nanomolar
Effector that Disrupts the Intramolecular
ALC1 ATPase–Macrodomain Interaction
(A) ITC isotherms between the ALC1 macrodomain
and mono-, di-, and tri-ADP-ribose. The Wiseman
plot was not baseline subtracted to account for the
heat of dilution of the ligands.
(B) SDS-PAGE of a V5-tagged ALC1 macrodomain
pull-down with ALC1’s ATPase. Addition of tri-ADP-
ribose disrupts the interaction (lane 6 versus lane
3–5). In contrast, an ADP-ribose-binding pocket
mutant (G750) suppresses the ability of tri-ADP-
ribose to compete off the ALC1 ATPase module.
Abrogation of the ATPase–macrodomain module
interaction by tri-ADP-ribose thus requires an intact
ADP-ribose binding pocket in the ALC1 macro-
domain. The asterisk denotes anti-V5 IgG heavy
chain.
(C) ITC isotherm for the interaction between the
ALC1 macrodomain and ATPase in the presence
(red squares) and absence (black circles) of tri-
ADP-ribose. The Wiseman plot was not baseline
subtracted.
See also Figure S3 and Table S2.between the ALC1 macrodomain module and tri-ADP-ribose
(Figures 3A and S3; Table S2). ALC1 seems unique among
known macrodomain proteins in showing strong preference for
oligo-ADP-ribose.
Our quantitative assays show that the ALC1 macrodomain
reads oligomers of ADP-ribose. It can thus discriminate PAR
and PARylation from other monomeric NAD+ metabolites and
mono-ADP-ribosylated proteins. We hypothesize that the sec-
ond and third ADP-ribose units of tri-ADP-ribose mediate addi-
tional contacts with ALC1 that extend beyond the protein’s
canonical ADP-ribose binding pocket, consistent with PAR foot-
printing data (Gottschalk et al., 2012).
Tri-ADP-Ribose Releases ALC1’s Auto-Inhibition
The ability of tri-ADP-ribose to bind the ALC1macrodomain with
nanomolar affinity and high selectivity gives us a probe to dissect
the allosteric activation of ALC1. We thus tested whether di- and
tri-ADP-ribose mimic PAR at the functional level and disrupt
ATPase–macrodomain interactions in vitro. V5-based pull-
downs with tagged ALC1macrodomain complexed to untagged
ATPase show that the addition of di-ADP-ribose does not de-
tectably affect interactions (Figure 3B; lane 5 versus lane 3). In
contrast, addition of tri-ADP-ribose (in 2.5-fold molar excess)
disrupts interactions between the two ALC1modules (Figure 3B;
lane 6 versus lane 3). Importantly, polyA-DNA does not cause864 Molecular Cell 68, 860–871, December 7, 2017macrodomain dissociation from the ALC1
ATPase, nor tri-ADP-ribose added to a
PAR-binding deficient G750Emacrodomain
mutant (Figure 3B; lanes 7–9 versus lane 3).
This indicates that trimeric ADP-ribose is
sufficient to disrupt the intermolecular asso-
ciation between the two ALC1 modules. To
quantitate the change in affinity between
the two domains in the presence of the tri-ADP-ribose ligand, we conducted ITC assays of the ALC1 mac-
rodomain with the ALC1 ATPase in the presence and absence of
equimolar tri-ADP-ribose. Tri-ADP-ribose reduces the affinity
between the two ALC1modules from70 nM to below detection
(KD = > 50 mM; Figure 3C; Table S2). Tri-ADP-ribose thus reduces
the affinity of the ALC1 macrodomain for the ATPase by at least
three orders of magnitude. While we have been unable to obtain
longer ADP-ribose oligomers, we conclude that the tri-ADP-
ribose probe is an effective PAR mimic.
The NAD+ Metabolite Tri-ADP-Ribose Induces
Conformational Changes within ALC1
Our assays indicate that tri-ADP-ribose may act as an allosteric
trigger of the conformation and enzymatic activity of ALC1. To
investigate how tri-ADP-ribose alters the structure of ALC1, we
used H/D-exchange (HDX) measurements monitored by mass
spectrometry (HDX-MS) to identify regions within ALC1 where
the hydrogen bonding of the amide groups of the protein back-
bone change upon tri-ADP-ribose addition. Peptide segments
resulting from pepsin proteolysis of ALC1, collectively covering
82.2% of the full-length sequence, were analyzed and used to
resolve the HDX of ALC1 regions with andwithout tri-ADP-ribose
(Figures 4A, S4, and S5). Upon binding tri-ADP-ribose, HDX-MS
reveals increases in HDX corresponding to an increase in dy-




Figure 4. Ligand-Induced Ungating of the Auto-Inhibited ALC1
Remodeler
(A) HDX-MS analysis reveals concerted destabilization of H-bonding in ALC1
upon tri-ADP-ribose binding. IncreasedHDX is observed in peptides located in
lobe 2 of the ALC1ATPase (HDX1 andHDX2; residues shown) and surrounding
the canonical ADP-ribose binding pocket of the ALC1 macrodomain (HDX3).
Differences in HDX (ΔHDX, colored lines) between the unbound and ligand-
bound state of ALC1 are plotted on the y axis with peptide number from N
terminus to C terminus on the x axis. Negative values indicate increased HDX
upon ligand binding. Values represent means of three independent measure-
ments, and gray bars illustrate the sum of ΔHDX values for all sampled time
points. Negative values indicate increased HDX upon ligand binding. Asterisks
indicate ALC1 regions that were not resolved by MS (gray; see also Figure S4).
Samples were incubated with D2O for 0.25 min (orange), 1 min (red), 10 min
(blue), and 60 min (green). The difference in HDX was considered significant if
>0.5 (blue dashed line), corresponding to a 98.75% confidence interval; n = 3.
(B) HDX results for ALC1 in the presence or absence of tri-ADP-ribose shown on
I-TASSER (Roy et al., 2010) structural models of the ALC1 macrodomain and
ATPase. Peptides that show a difference in HDX upon addition of tri-ADP ribose
arecoloredpurple in themacrodomain (top,HDX3) andgreen/lime in theATPase
(bottom, HDX1 andHDX2). The linker connecting the ATPase andmacrodomain
is shown as a dotted line (right). Its structure is not known, and it is largely not
covered by our HDX data. Residues shown include R857 within the macro-
domain’s HDX3 region, a residue whose mutation is implicated in human gli-
omas, and the catalytic E175 in the ATPase as a reference for ALC1’s active site.
(C)Mutationalanalysis ofHDX1,HDX2,andHDX3using theF2H-basedATPase–
macrodomain interaction assay. We targeted residues within HDX regions that
contained patches of negative or positively charges, including the somatic
cancerSNPs (R85Q,R842H, andR860W). Errorbar represents theSEM,nR20.
See also Figures S4 and S5.changes within two neighboring segments encompassing a pre-
dicted a-helix in the ALC1macrodomain, which lies in immediate
proximity to the canonical mono-ADP-ribose ligand binding site
(residues 832–858; HDX3; Figure 4B). This is consistent with the
binding of tri-ADP-ribose within and near the canonical macro-
domain pocket, leading to an altered H-bonding environment
for residues involved in either (tri-) ADP-ribose interaction
and/or intramolecular ALC1 contacts. Remarkably, tri-ADP-
ribose binding to the ALC1 macrodomain also changes the
HDX pattern of residues which are located in lobe 2 of the Snf2
ATPase, specifically residues 319–357 (HDX1) and 392–415
(HDX2; Figures 4A and 4B), which show distinct HDX increase.
This indicates that the binding of tri-ADP-ribose to the macrodo-
main module of the ALC1 remodeler is associated with
concerted changes in the H-bonding of regions in lobe 2 of the
ATPase (Figure 4B).
Interestingly, in yChd1 and ISWI, the surface of the ATPase
lobe 2 contacts the protein’s chromodomain 1 and NTR region,
respectively. This allows the remodelers to gate access of DNA
to the ATPase motor. Our HDX-MS data reveal a destabilization
of H-bonding and increased dynamics of lobe 2 within the ALC1
ATPase motor upon the binding of tri-ADP-ribose. Moreover, we
observe tri-ADP-ribose-induced changes also near the canoni-
cal ADP-ribose binding pocket of the ALC1 macrodomain.
HDX-MS data thus identify regions of ALC1 that undergo
H-bond destabilization and conformational gating upon the allo-
steric activation induced by tri-ADP-ribose. We hypothesize that
PAR binding to ALC1 may grant access of the ATPase motor to
nucleosomal DNA, switching ALC1 into an ‘‘ungated’’ conforma-
tion that hydrolyzes ATP and slides nucleosomes.
Somatic Cancer Mutants Drive the Ungating of ALC1
To test whether the surface regions identified in our HDX-MS as-
says are important for the intramolecular interactions and enzy-
matic regulation of ALC1, we engineered point mutants in HDX1,
HDX2, and HDX3 and tested how they affect ATPase–macrodo-
main interaction using F2H assays (Figure 4C). To increase the
dynamic range of our assay, we used the ALC1 macrodomain
G750E mutant, which binds PAR with lower affinity, as a refer-
ence. Interestingly, residues R857, R842, and R860 are mutated
in human gliomas (Bamford et al., 2004). We find that the cancer
SNPs R857Q and R842H/R860W, when introduced into the
ALC1 macrodomain, reduce interaction with the ALC1 ATPase
(Figure 4C). Similarly, point mutants within HDX1 and HDX2 of
the ATPase module reduce ALC1 ATPase–macrodomain inter-
actions (Figure 4C). We conclude that ALC1 regions identified
in our HDX-MS analysis contribute to intramolecular ATPase–
macrodomain interactions. Binding of tri-ADP-ribose to ALC1
disrupts intramolecular contacts that are critical for ALC1’s
auto-inhibition.
A Tethered ALC1 Fragment Remodels Chromatin In Vivo
The ability of PAR to activate ALC1 by releasing the interaction of
ALC1’s ATPase from the macrodomain predicts that ALC1
ATPase fragments lacking the PAR-regulated macrodomain
might display chromatin remodeling activity in vivo, and without
requiring PARP1 activation. Since PARP1 activation in vivo leads
massively relaxes chromatin upon DNA damage and ALC1Molecular Cell 68, 860–871, December 7, 2017 865
mediates this chromatin plasticity (Sellou et al., 2016), we
decided to use an in vivo chromatin relaxation assay to test the
function of engineered ALC1 macrodomain-deletion fragments.
Since ALC1 does not recruit to chromatin uponDNAdamage in
the absence of its PAR-binding macrodomain, we tethered
full-length, fragment, and mutant LacI-ALC1 fusions to an
integrated LacO array in human cells. As expected, wild-type,
full-length ALC1 (1–897) does not alter the LacO-array when teth-
ered to the LacO-array (Figure 5A). In sharp contrast, when the
macrodomain of ALC1 is deleted, the ALC1 fragment (residues
1–673) decompacts the LacO array (Figure 5A). This chromatin
relaxation is seen with other ALC1 C-terminal fragments, but not
in a fragment as short as 1–614. This indicates that sequences
within linker II of ALC1 (residues 615–673; Figure 1A) promote
chromatin remodeling activity, while the macrodomain is inhibi-
tory to ALC1 in vivo. Importantly, mutation of conserved residues
within the ALC1 helicase that disrupt ATPase activity (Ahel et al.,
2009; Gottschalk et al., 2009) abolishes ALC1-induced chromatin
relaxation (Figure 5A). Tethered ALC1 fragments lacking themac-
rodomain thus possess remodelingactivity in the absence ofDNA
damage induction and PARP1 activation.
Next, we tested whether the macrodomain of ALC1 alters the
inherent chromatin remodeling activity of the LacI-tethered
ALC1 ATPase (1–673) construct when added in trans. Addition
of the ALC1 macrodomain module to the active, tethered
ALC1 ATPase reduces chromatin decompaction (Figure 5A).
A PARP1 inhibitor enhances this inhibition. Our data indicate
that the ALC1 macrodomain inhibits the ATPase activity of
ALC1 at physiological levels of PARP1 activity. In its absence,
a tethered ALC1 ATPase module remodels chromatin in vivo.
Tri-ADP-Ribose De-represses the ATPase Activity of the
ALC1 Remodeler
Our LacO-tethering assay identified a constitutively active ALC1
ATPase fragment (1–673), whose activity can be suppressed by
addition of the ALC1macrodomainmodule. Since tri-ADP-ribose
promotes the dissociation of the ALC1 macrodomain from the
ALC1 ATPase module, we sought to determine the relevance of
tri-ADP-ribose binding on the catalytic activity of the ALC1 re-
modeler. We established a robust, DNA-dependent ATPase
assay for both the ALC1 ATPase module (31–673) and the
(near) full-length ALC1 protein (31–878). We find that the ALC1
ATPase module shows robust, DNA-dependent ATPase activity
(Figure S6). Importantly, titration of the ALC1macrodomainmod-
ule to the ALC1 ATPase lowers ATPase activity (Figure S6). Once
a 2.5 molar excess of ALC1 macrodomain is added to the ALC1
ATPase, the resulting complex is inactive, revealing background
ATPase activity similar to that of the ALC1 ATPase without DNA.
The ALC1macrodomain thus represses the inherent ATPase ac-
tivity present in the ALC1 ATPase module.
Next, we tested whether the addition of the nanomolar tri-
ADP-ribose ligand of ALC1 alters the ATPase activity of the
enzyme in vitro. Addition of a 2-fold molar excess of tri-ADP-
ribose to the inactive ALC1 ATPase–macrodomain complex
robustly de-represses the ALC1 ATPase, going from <2%
without tri-ADP-ribose to 60% of the activity of the free ALC1
ATPase module (Figure 5B). Importantly, addition of a 6-fold
molar excess of mono-ADP-ribose to the ATPase–macrodomain866 Molecular Cell 68, 860–871, December 7, 2017complex fails to rescue ATPase activity (Figure 5B), consistent
with the lack of binding of monomeric ADP-ribose for the ALC1
macrodomain (Figure 3A). Thus, tri-ADP-ribose binding to the
ALC1 ATPase–macrodomain complex strongly activates the
ATPase activity of the ALC1 remodeler.
In addition, we testedwhether tri-ADP-ribose alters the activity
of (near) full-length ALC1. As expected, theATPase activity of this
construct is low, including in the presence of mono-ADP-ribose.
However, tri-ADP-ribose strongly activates the ATPase activity in
the ALC1 remodeler (Figure 5C). The level of activation (fold
induction) induced by tri-ADP-ribose is lower than in our assays
using the reconstituted ALC1 complex. However, this is likely
the result of degradation products present in our recombinant
ALC1 (31–878) construct (Figure S6). Indeed, someof the proteo-
lytic fragments observed in our ALC1 construct (31–878) likely
lack (parts of) the inhibitory macrodomain and may thus display
catalytic ATPase activity independently of the tri-ADP-ribose
trigger. Our assays show that tri-ADP-ribose is a potent activator
of the DNA-dependent ATPase activity of the ALC1 remodeler.
Somatic Cancer Mutants in ALC1 Drive Chromatin
Remodeling
We identified cancer SNPs located within the HDX3 region of the
ALC1 macrodomain, which lead to a loss-of-interaction pheno-
type between the ALC1 ATPase and macrodomain (Figure 4C).
We thus tested the effect of these mutant macrodomains on
the activity of the constitutively active ALC1 ATPase tethered
to the LacO array when expressed in trans. Interestingly, the
point mutants R857Q and R842H/R860W show a decompaction
of the LacO similar to that of the constitutively active ALC1
ATPase module without any macrodomain expressed in trans.
In sharp contrast, co-expression of the wild-type macrodomain,
or of the G750E macrodomain mutant, strongly reduces the de-
compacted area, indicating that these macrodomain constructs
inhibit the remodeler activity in trans and in vivo (Figure 5A).
Furthermore, FCS assays in the context of the full-length ALC1
protein show a decreased diffusion behavior of the HDX1 and
HDX3 mutants compared to wild-type ALC1 (Figure S6). This
suggests that HDX mutants that disrupt the intramolecular
ATPase–macrodomain interactions promote an ungated struc-
ture in ALC1, which may potentially lead to increased DNA
binding. Taken together, our data show that somatic cancer
mutations phenocopy the activity of the constitutively active
ALC1 ATPase fragment. While the relevance for this in cancer
remains to be established, our tethering assay indicates that mu-
tations in ALC1 that disrupt its inhibitory intra-molecular interac-
tions (Figure 4C) promote the deregulated, constitutive activity of
this chromatin remodeler (Figure 5A).
Modular Allostery in ALC1 Regulates Interaction
with PARP1
To further probe the PAR-regulated modular allostery in ALC1,
we tested whether, in turn, the ATPase module affects the ability
of the ALC1 macrodomain to recognize its effector molecule,
PARylated PARP1, in living cells. While full-length ALC1 does
not readily interact with full-length PARP1 in untreated
human cells using the F2H assay (Figure 5D; Movie S3), DNA




Figure 5. Release from Auto-Inhibition Drives
ALC1’s Chromatin Remodeling Activity
(A) Tethering of engineered mCherry-LacI-ALC1
to an integrated LacO array decompacts chromatin
in U2OS cells (representative images; top). The de-
compaction of the LacO array is calculated as
percent of the nucleus area (bottom). The deletion
of ALC1’s macrodomain generates a constitutively
active ALC1 that decompacts the LacO-array
in vivo. Constructs assayed: full-length ALC1
(1–897), macrodomain deletion (1–707), a hyperac-
tive construct (1–673), ATPase-dead point mutation
(1–673, E175Q), plus ALC1 (1–614), which repre-
sents the ATPase module identified in our limited
proteolysis (Figure S1). Importantly, co-transfection
of the ALC1 macrodomain (mEGFP-616–897) with
the constitutively active ALC1 fragment (1–673)
reduces the decompacted area. Further, cancer
SNPs within HDX3 that disrupt interaction with the
ATPase module (Figure 4C) do not decrease the
chromatin decompaction catalyzed by the ALC1
ATPase (1–673) module. Error bar represents the
SEM, n R 20.
(B) Tri-ADP-ribose de-represses the ATPase activity
of the inactive ALC1 ATPase–macrodomain com-
plex. The DNA-dependent ATPase activity of the
ALC1 ATPase module was measured using a mal-
achite green assay in the presence and absence of a
2.5 molar excess of ALC1 macrodomain module, as
well as in the absence (left) or presence of either a
6-fold molar excess of ADP-ribose (middle) or a
2-fold molar excess of tri-ADP-ribose (right). The
data are normalized to the respective mean activity
of the ATPase module alone (black bars; n = 3;
mean ± SEM).
(C) Tri-ADP-ribose promotes the activation of the
ALC1 chromatin remodeling enzyme. The (near) full-
length ALC1 construct (31–878) shows only basal
ATPase activity in the absence or presence of a
15-fold molar excess of ADP-ribose. In contrast, a
5-fold molar excess of tri-ADP-ribose greatly stim-
ulates ALC1-catalyzed and dsDNA-dependent ATP
hydrolysis. The data are normalized to the mean
value of ALC1 activity in the presence of tri-ADP-
ribose (n = 3; mean ± SEM).
(D) F2H assay testing the interaction of tethered
ALC1 macrodomain (wild-type, WT; G750E mutant)
with fluorescently tagged PARP1 (wild-type and
E988K PAR elongation mutant). Indicated experi-
ments were done in the presence of a PARP1 in-
hibitor (+PARPi) or H2O2. Error bar represents the
SEM, n R 20.
See also Figure S6.these two proteins, consistent with the recognition of activated,
PARylated PARP1 by ALC1. Interestingly, an ALC1 fragment
lacking the catalytic ATPase domain readily interacts with
PARP1, even in the absence of exogenous DNA damage (Fig-
ure 5D). Treatment of cells with a PARP1 inhibitor abrogates
this interaction. This indicates that the isolated macrodomain
of ALC1 recognizes ADP-ribosylated forms of PARP1 under
‘‘non-DNA-damage’’ conditions (Figure 5D), likely reflectingbackground ADP-ribosylation. Consistently, a point mutant in
the ALC1 macrodomain that reduces PAR binding (G750E),
or mutation of a key residue in PARP1 (E988K) that is responsible
for the elongation of mono-ADP-ribosyl-PARP1 to poly-ADP-ri-
bosyl-PARP1, disrupts the interaction between the ALC1macro-
domain and PARP1 (Figure 5D). We conclude that the isolated
ALC1 macrodomain interacts with ADP-ribosylated PARP1 un-
der physiological conditions, while full-length ALC1 requires aMolecular Cell 68, 860–871, December 7, 2017 867
Figure 6. Modular Allostery Sets a Threshold for
PARP1-Induced ALC1 Activation
Modular allostery in the chromatin remodeler ALC1
regulates auto-inhibition through the reciprocal inter-
action of ALC1’s ATPase and macrodomain modules.
This helps to ensure that the PARP1 product PAR acts
as an allosteric activator and potent trigger of ALC1-
promoted chromatin relaxation only once acute DNA
damage has induced PARP1 activity.high threshold of DNA damage and PARP1 activation in order to
interact with PARylated PARP1. Thus, the ATPase of ALC1
lowers the affinity of the macrodomain for PARylated-PARP1,
consistent with modular allostery. We suggest that the modu-
larity of ALC1 allows the remodeler to be activated only once a
threshold of PARP1 activation has been reached.
DISCUSSION
Auto-inhibitory interactions play important roles in signaling and
in the regulation of chromatin and repair factors (DaRosa et al.,
2015; Guo et al., 2015). Considering the emergent role of remod-
elers in cancer (St Pierre and Kadoch, 2017; Zhao et al., 2017), a
better understanding of how DNA damage alters chromatin is
important. While the mechanisms that ALC1 and CHD2 employ
to relax chromatin upon DNA damage in vivo (Movie S1) are not
known, and the remodelers’ substrate(s) in vivo remains to be
identified, herewehave identified anddissected themechanisms
that allow the oncogeneALC1 to be tightly regulated by theNAD+
metabolite PAR (Figure 6). We show that reciprocal interactions
between the ALC1 ATPase and its macrodomain allow ALC1 ac-
tivity to be controlled by PARP1 activation. The binding of an olig-
omer of at least three ADP-ribose units to ALC1’s macrodomain
triggers conformational changes that disrupt auto-inhibitory in-
teractions. This ‘‘ungates’’ the ATPase module, promoting
DNA-dependent ATPase activity in vitro and remodeling in vivo
(Figures 3, 4, and 5). Modular allostery thus ensures that ALC1
is exquisitely sensitive to and selective for oligomeric forms of
ADP-ribose. We infer that PAR acts as a catalytic trigger only
once a threshold of PARP1 induction has been reached. Most
‘‘reader’’ modules in chromatin biology are thought to play a
recruitment and tethering function. Our identification of a recip-
rocal interactionbetweenaPAR-bindingmacrodomain (‘‘reader’’
module) and the catalytic ATPase module of ALC1 adds to the
allostery described for DNA methyltransferases (Guo et al.,
2015; Jeltsch and Jurkowska, 2016).868 Molecular Cell 68, 860–871, December 7, 2017In vivo, binding of the PAR effector to
the macrodomain occurs when ALC1 re-
cruits to DNA damage sites, which tethers
the remodeler to chromatin and allows
ALC1 to remodel chromatin. Our study
does not identify the specific, physio-
logical substrate that ALC1 remodels on
chromatin. Swi2/Snf2 remodelers such
as Mot1 remodel non-nucleosomal sub-
strates (Wollmann et al., 2011). In vivo, the
PARylation of histones, PARP1, ALC1, and/or other chromatin factors may thus contribute to how ALC1
catalyzes chromatin relaxation.
The selectivity of ALC1 toward oligo-ADP-ribose, and the fact
that the enzyme’s ATPase impairs the ability of ALC1’smacrodo-
main to bind PARP1 under non-DNA damage conditions (Fig-
ure 5D), likely helps to ensure that PARP1-dependent chromatin
relaxation is only catalyzed once PARP1 has been activated,
such as during DNA damage. Our data reveal how the ATPase
activity of a remodeler is gated by the PARP1-product and
nucleic acid PAR through regulatory interactions mediated
by ALC1’s macrodomain. This adds to our mechanistic under-
standing of how the ATPase activity of chromatin remodelers is
regulated. Further work will be necessary to dissect how poly-
ADP-ribosylated PARP1 promotes the efficient remodeling of
nucleosomes. Our data show that in the special case of ALC1,
tethering and activation occur through a NAD+metabolite, which
acts as an allosteric ATPase trigger, in a mechanism mediated
by the remodeler’s core macrodomain fold and additional con-
tacts with the PAR ligand.
Our analysis also identifies how the oncogene ALC1 might be
targeted in cancer. Small molecules that inhibit its allostery or ac-
tivity should reproduce ALC1 knockdown phenotypes, such as
reduced tumor growth, reduced reprogramming, and increased
sensitivity to chemotherapy (Jiang et al., 2015; Liu et al., 2016).
Compounds that stabilize the inactive, gated conformation of
ALC1, which lower its catalytic activity, or that disrupt its ability
to recognize PAR should suppress the potent chromatin relaxa-
tion activity of this oncogene.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-mCherry-antibody Novus Bio NBP2-25157
Bacterial and Virus Strains
Escherichia coli DH5 alpha Thermo-Fisher Scientific 18265017
Escherichia coli Rosetta (DE3) pLysS
Competent Cells - Novagen
Merck Millipore 70956
Escherichia coli DH10MultiBac Geneva Biotech DH10MultiBac
Spodoptera frugipeda Sf21 insect cells ThermoFisher Scientific
(Invitrogen)
11497013
Trichoplusia ni High Five insect cells ThermoFisher Scientific
(Invitrogen)
B85502
Chemicals, Peptides, and Recombinant Proteins




Homo bi-functional cross-linker BS3 ProteoChem c1103
Ammonium bicarbonate (NH4HCO3) Sigma 09830
DMSO Life Technologies D12345
Trypsin Promega V511B
Sep-Pak tC18 Cartridges Waters WAT043410
PARP1inhibitor AG14361 Selleck Chemicals S2178
Di- and tri-ADP-ribose (Kistemaker et al., 2015) N/A
Adenosine 50-diphosphoribose (ADPr) Sigma A0752
DMEM Dulbecco’s Sigma S5796
FBS GIBCO 10270




Hygromycin B Sigma H3274
CO2-independent imaging medium GIBCO by Life technologies 18045-054
Cell culture Dulbecco’s PBS Sigma D8537
Critical Commercial Assays
SYPRO Orange, 5000x in DMSO Sigma S5692
Biomol Green Enzo Life Sciences BML-AK111
Gel filtration calibraton kit, Low Molecular Weight GE Healthcare 17-0442-01
Gel filtration standards BioRad 151-1901
384-well Microplates; ATPase assay Greiner Bio One 781101
Borosilicate 8-well LabTeks Thermo-Scientific 155411
X-fect transfection reagent Clontech 631317
GFP-Trap_A Chromotek gta-20
Experimental Models: Cell Lines
Human U2OS cells harboring the stably
integrated lacO (256x) array
(Soutoglou and Misteli, 2008) N/A
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REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pmCherry-C1 Vector This study See Table S3
pmCherry-LacI-C1 This study See Table S3
pmCherry-N1Human SSRP1 This study See Table S3; digested with XhoI and HindIII
and cloned into mCherry-N1 vector
pEYFP-ALC1-1-897-C1 (Gottschalk et al., 2009) N/A
pmCherry-LacI-ALC1-1-897-C1 This study See Table S3
pmCherry-LacI-ALC1-1-706-C1 This study See Table S3
pmCherry-LacI-ALC1-1-673-C1 This study See Table S3
pmCherry-LacI-ALC1-1-614-C1 This study See Table S3
pmEGFP-LacI-ALC1-616-897-C1 This study See Table S3; subcloned from pEYFP-ALC1-1-
897-C1 between BglII-EcoR1
pmCherry-LacI-ALC1-616-897-C1 This study See Table S3; subcloned from pmEGFP-LacI-
616-897-C1; BglII and EcoR1
pEYFP-ALC1-1-614-C1 This study See Table S3
pmEGFP- ALC1-1-897-C1 This study See Table S3; subcloned from pEYFP-ALC1-1-
897-C1 (Restriction sites BglII and ECoR1)
pmEGFP-ALC1-616-897-C1 This study See Table S3; subcloned from pmEGFP-LacI-
616-897-C1; Restriction sites BglII and EcoR1
pET-MCN-ALC1-31-878 This study See Table S3
pET-MCN-ALC1-31-615 This study See Table S3
pET-MCN-ALC1-31-605 This study See Table S3
pET-MCN-ALC1-616-876 This study See Table S3
pET-MCN-V5-ALC-616-876 This study See Table S3
pET-MCN-ALC-636-876 This study See Table S3
pETM-11: ALC1 31-673 This study See Table S3
pmEGFP-C1Human Spt16 This study See Table S3
pFBDM-TWINStrep-ALC1-1-897 This study See Table S3
pcDNA3eYFP-Af1521-macrodomain (Timinszky et al., 2009) N/A
pcDNA3eYFP-macroH2A1.1-macrodomain (Timinszky et al., 2009) N/A
pcDNA3eYFP-macroH2A1.2-macrodomain (Timinszky et al., 2009) N/A
pET-MCN-V5-ALC-616-876: G750E This study See Table S3
pmEGFP-ALC1-616-897-C1: G750E This study See Table S3
pmEGFP-ALC1-1-897-C1: G750E This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: E175Q This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: EPEPFE/APAPAA This study See Table S3
pmEGFP-ALC1-1-897-C1: EPEPFE/APAPAA This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: PEPFE/PAPAA This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: RK319/320EE
-KR407/422DE
This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: KR407/422DE This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: KK307/
308EE-K398E
This study See Table S3
pmCherry-LacI-ALC1-1-614-C1: S420A This study See Table S3
pmEGFP-ALC1-616-897-C1: 653-KRRR-656/
AAAA-G750E
This study See Table S3
pmEGFP-ALC1-616-897-C1: R857E/G750E This study See Table S3
pmEGFP-ALC1-616-897-C1: R857Q/G750E This study See Table S3
pmEGFP-ALC1-1-897-C1: R857Q This study See Table S3
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pmEGFP-ALC1-616-897-C1: R842H/
R860W/G750E
This study See Table S3
pmEGFP-ALC1-1-897-C1: R842H/R860W This study See Table S3
pmEGFP-ALC1-1-897-C1: R842H This study See Table S3
pmEGFP-ALC1-1-897-C1: R860W This study See Table S3
Software and Algorithms






MS Convert Proteowizard Tools http://proteowizard.sourceforge.
net/tools.shtml
N/A
Crossfinder (Mueller-Planitz, 2015) N/A






FIJI(ImageJ) (Schindelin et al., 2012) N/A
Fluctuation Analyzer 4G software (Wachsmuth et al., 2015) N/A
Other
Superdex 200 Increase 10/300 GL GE Healthcare 28990944
15-cm analytical column C18 nanocolumn
(75 mm ID homepacked with ReproSil-Pur
C18-AQ 2.4 mm)
N/A N/A
Ultimate 3000 HPLC system ThermoFisher Scientific IQLAAAGABHFAPBMBFBCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Andreas
G. Ladurner (andreas.ladurner@bmc.med.lmu.de).
METHOD DETAILS
Cloning, protein expression and purification
All human ALC1 fragments and mutants were engineered by sub-cloning and site-directed mutagenesis, using oligonucleotides
defined in Table S3. Recombinant proteins were expressed and purified as N-terminally 6 3 His-tagged fusion proteins from
E. coli Rosetta (DE3) pLys using pETM-CN or pETM-11 (only for ALC1 31-674) vectors. Starting cultures were grown in LB-medium
supplemented with the appropriate antibiotics over night at 30C and used at a 1:50 dilution to inoculate the expression cultures.
Expression cultures were then grown in rich medium (supplemented with antibiotics) at 37C and 160-200 rpm until reaching an
OD600 of 0.6 – 0.8 before protein expression was induced with 0.2 mM isopropyl b-D-1 thiogalactopyranoside (IPTG). After induction,
protein expression was allowed to proceed for 18 hr at 18C (ALC1 570-897, 31-605, 31-615, 615-876, V5-615-876, 636-878) or 16C
(ALC1 31-674, 3-897, 31-878) until the cells were harvested by centrifugation at 8,000 3 g for 10 min. Bacterial pellets were either
directly used for protein purification or stored at 80C. The cells were lysed by sonication at 4C in lysis buffer (50 mM Tris-HCl
pH 7.5, 500 mM NaCl, 20 mM imidazole, 5 mM dithiothreitol (DTT) and Complete EDTA free protease inhibitor tablets (Roche).
The lysate was cleared by centrifugation at 45,0003 g and loaded onto Ni-Sepharose 6FF beads for batch purifications or a HisTrap
HP 1mL column operated on a ÄKTA pure FPLC system (GE Healthcare). After washing with several (15-30) column volumes (CV)
lysis buffer, proteins were eluted either stepwise (batch purification) or in a 15 CV gradient of elution buffer (lysis buffer supplemented
with 500 mM imidazole). The eluate was concentrated by ultrafiltration (Vivaspin 30,000 MWCO, Sartorius) and loaded onto a Super-
dex 200 16/60 column (GE Healthcare) equilibrated in SEC-buffer (25 mM Tris-HCl pH 7.5, 200 mMNaCl, 1 mMDTT). Peak fractions
were pooled and diluted with dilution buffer (25 mM Tris-HCl pH 7.5, 2 mM DTT) to a final salt concentration of 50 mM NaCl (low-salt
buffer) and loaded onto a cation exchange column (MonoS 5/5 HR or Resource S 6mL (GE Healthcare), full length andMacro domain
constructs), or an anion exchange column (MonoQ 5/5 HR or Resource Q 6mL (GE Healthcare), ATPase constructs) pre-equilibrated
with low-salt buffer. After washing with 5-10 CV low-salt buffer, proteins were eluted by increasing the NaCl concentrations toe3 Molecular Cell 68, 860–871.e1–e7, December 7, 2017
500 mM in a linear gradient of 10-20 CV. Peak fractions were again pooled and concentrated by ultrafiltration (Vivaspin 30,000
MWCO, Sartorius). The purified proteins were either used directly or snap-frozen in liquid nitrogen for storage at 80C. For the
ITC assays, the macrodomain of macroH2A1.1 was expressed and purified, as published (Kustatscher et al., 2005; Timinszky
et al., 2009). Briefly, N-terminally 63 His-tagged of MacroH2A1.1 (residues 162-369) was expressed for 3 hr at 37C after induction
with 1 mM IPTG. The cells were lysed in 50 mM Tris-HCl pH 7.4, 500mMNaCl, 1 mMMgCl2, 5 mM b-ME and 10% (v/v) glycerol. The
proteinwas bound to Ni-Sepharose 6FF beads, washedwith lysis buffer containing 1MNaCl and 40mM imidazole, and eluted in lysis
buffer supplemented with 500 mM imidazole. The ALC1 macrodomain and the ALC1 ATPase module were purified as
described above.
Limited trypsin proteolysis
500 ml of purified Hs ALC1 (3-897; full-length) or Hs ALC1 (570-897; macrodomain) at a concentration of 1 mg/ml were incubated at
room temperature (RT) with trypsin (Sigma Aldrich) at a ratio of 1:100 (full-length) and 1:10 (macrodomain). Reactions were stopped
by addition of protein gel loading buffer and boiling (for SDS-PAGE analysis) or 2 mM PMSF (final; for analytical SEC analysis). The
resulting major bands on the SDS-PAGE gels were used for MALDI peptide mass fingerprinting to identify the peptides correspond-
ing the particular band.
Full-length ALC1 baculovirus cloning expression and purification
Full length human ALC1 (1-897) was expressed as N-terminally Twin-Strep-tagged fusion protein using MultiBac technology (Fitz-
gerald et al., 2006). Briefly, cDNAwas cloned into pFBDMvector for expression under control of a polyhedrin promotor. Transposition
into MultiBac baculoviral DNA was performed in E. coli DH10MultiBac cells (Geneva Biotech). Isolated bacmid DNA was transfected
into Spodoptera frugipeda Sf21 insect cells (Invitrogen) in order to generate baculovirus, while large-scale protein expression was
carried out using Trichoplusia niHigh Five insect cells (Invitrogen). High Five cells were infectedwith 1/100 (v/v) with baculovirus. Cells
were cultured for 60 hr at 27C until they were harvested by centrifugation. Cells were lysed by gentle sonication in lysis buffer (20mM
HEPES pH 8.0, 500 mM NaCl, 10% [v/v] Glycerol, 2 mM MgCl2, 1 mM DTT) and complete EDTA free protease inhibitor tablets
(Roche). The lysate was cleared by centrifugation and loaded onto Streptactin-Sepharose (IBA) for batch purification. After washing
beads with lysis buffer, protein was eluted using 3.5 mM d-Desthiobiotin (Sigma). The eluate was concentrated by ultrafiltration (Vi-
vaspin 30,000 MWCO, Sartorius) and loaded onto a Superdex 200 16/60 column (GE Healthcare) equilibrated in SEC-buffer (20 mM
HEPES pH 8.0, 500mMNaCl, 10% [v/v] Glycerol, 2 mMMgCl2, 1mMDTT). Purified, monodisperse ALC1 protein was snap-frozen in
liquid nitrogen for storage at 80C.
Hydrogen deuterium exchange mass-spectrometry (HDX-MS)
For HDX labeling: All proteins were incubated for 30min at 25Cbefore initiating the labeling reactions. Deuterated buffer (2.5mMTris
(pH 7.5), 150 mM NaCl, 0.1 mM DTT) was added in a 10:1 dilution (v/v), resulting in 90% (v/v) D2O and 0.8 mM protein concentration
during labeling. The reactions were incubated for various time intervals ranging from 0.25 to 60 min. The following labeling reactions
were prepared in duplicates unless otherwise specified: a) A full time series of the full length ALC1 with and without 5-fold molar
excess of tri-ADP-ribose. Single measurements were conducted for the entire time series and from the results, two time points
(0.25 and 10 min) were selected for triplicate measurements. b) A 10 min time point of the full length ALC1 with and without
50-fold molar excess of tri-ADP-ribose. c) A 0.25 min time point of the Macrodomain with and without 5-fold molar excess of tri-
ADP-ribose or 50-fold molar excess of mono-ADP-ribose). d) A 0.25 min time point of the 1:1 molar ratio mixture of the ATPase
domain and the Macrodomain with and without 5-fold molar excess of tri-ADP-ribose. Following the indicated incubation periods,
the labeling reactions were quenched by 1:1 (v/v) dilution into ice-cold quench buffer (219 mM potassium phosphate
(pH 2.5), 6 M urea). The quenched samples were immediately frozen and stored at 80C. For LC-MS and LC-MS/MS measure-
ments: Samples were quickly thawed and injected into a Waters nanoAcquity UPLC system with an HDX Manager which allows
for online digestion at 20C and desalting and separation of peptides at 0C. Following online digestion on column packed with im-
mobilized pepsin on agarose (Thermo Scientific Pierce, Rockford, USA), the peptic peptides were trapped on a C18 Vanguard trap
column (Acquity UPLC BEH C18 column, 130Å, 1.7 mm, 2.1mm X 5 mm – Waters – Product number: 186003975) and desalted for
3min with 0.23% formic acid in water (pH 2.5) at a flow rate of 200 ml/min. The peptides were eluted from the trap column to an analyt-
ical column (Acquity UPLCBEHC18 column, 130Å, 1.7 mm, 1mmX 100mm–Waters – Product number: 186002346) fitted with a C18
Vanguard column (Acquity UPLCBEHC18 column, 130Å, 1.7 mm, 2.1mmX 5mm–Waters – Product number: 186003975) and sepa-
rated using a 9min gradient from 8% to 40%of 0.23% formic acid in acetonitrile at a flow rate of 40 ml/min. The peptides were ionized
by electrospray ionization andmass spectra collected using aWaters Synapt G2 HDMSmass spectrometer set in positive ion mode.
Peptic peptides of non-deuteriated samples were identified in a separate experiment using collision-induced dissociation tandem
mass spectrometry with data collected in a data-independent (MSE)manner. Peptide identification was carried out using ProteinLynx
Global Server 3.0 and the HDX-MS data was processed using DynamX 3.0 from Waters.
Chemical cross-linking coupled to mass spectrometry (XL-MS)
Cross-linking reactions were carried out with 1 mMpurified ALC1 full-length protein in 25mMHEPESKOHpH 7.6, 0.1mMEDTA, 10%
glycerol, 100 mM KOAc, 1.5 mM MgCl2, 1 mM DTT. The homobifunctional cross-linker BS3 (ProteoChem) was dissolved freshly inMolecular Cell 68, 860–871.e1–e7, December 7, 2017 e4
DMSO and added to a final concentration of 1 mM. The cross-linking reactions and a mock-treated control were incubated on ice for
20 min before quenching with NH4HCO3 to a final concentration of 200 mM for 10 min. The protein sample was loaded onto a pre-
equilibrated Superdex 200 (Increase 10/300GL, GEHealthcare). The elution profile at 280 nmwas consistent with ALC1 beingmono-
meric in solution and no evidence for a possible dimer formation was observed. Protein fractions were pooled and concentrated by
the addition of 15% (w/v) trichloroacetic acid with pelleting. The pellet was washed twice with acetone and re-dissolved in 8 M urea.
In-solution digestion was performed after urea dilution with trypsin (enzyme to substrate ratio 1:50) at 37C overnight. Digestion was
stopped by the addition of 2% (v/v) formic acid. Acidified peptides were purified and concentrated by a C18 resin (Sep-Pak tC18
Cartridges, Waters). The eluate was dried by vacuum centrifugation and re-dissolved in 0.1% trifluoroacetic acid. To map the
cross-links by LC-MS/MS, samples were desalted offline using C18 Stagetip and injected in an Ultimate 3000 (Thermo) or RSLCnano
system (Thermo). Peptides were separated in a 15 cm analytical column C18 nanocolumn (75 mm ID homepacked with ReproSil-Pur
C18-AQ 2.4 mm from Dr. Maisch) with a 40 or 60 min gradient from 5 to 60% acetonitrile in 0.1% formic acid. The effluent from the
HPLC was directly electrosprayed into a Q Exactive HF (Thermo). The Q Exactive HF instrument was operated in data dependent
mode to automatically switch between full scan MS and MS/MS acquisition. Survey full scan MS spectra (from m/z 375–1600)
were acquired with resolution R = 60,000 at m/z 400 (AGC target of 3x106). The ten most intense peptide ions with charge states
between 3 and 5 were sequentially isolated to a target value of 1x105, and fragmented at 27% normalized collision energy. Typical
mass spectrometric conditions were: spray voltage, 1.5 kV; no sheath and auxiliary gas flow; heated capillary temperature, 250C;
ion selection threshold, 33.000 counts. Thermo binary raw file were transformed to mzXML files using msconvert (Proteowizard
Tools; proteowizard.sourceforge.net/tools.shtml). Cross-linked peptides were identified using Crossfinder (Mueller-Planitz, 2015).
An MS1 and MS2 tolerance window of 10 and 12 ppm, respectively, was applied. The number of missed trypsin cleavage sites
was set to three. For all peptides, oxidation of methionine was set as variable modification and carbamidomethylation as fixedmodi-
fication. All lysine residues were considered as potential cross-linking sites for BS3. False-discovery rates (FDRs) were estimated by
Crossfinder and results were filtered according the following parameters for identification of cross-linking candidates: FDR < 1%,
number of fragment ions per spectrum R 6, number of fragment ions per peptide R 3, number of fragment ions with cross-
linker R 1, fractional intensity of assigned MS2 peaks R 0.05, relative filter score: 100. We ensured that cross-linking candidates
were not present in the mock-treated sample. MS2 spectra of cross-linking candidates spanning at least 10 amino acids in the pri-
mary sequence were manually validated.
Isothermal titration calorimetry (ITC) assays
For ITC binding assays the Peaq-ITC instrument (Malvern) was used. Before the experiment, proteins were dialyzed overnight against
25mMTris, 100mMNaCl buffer (pH 7.5) and 5mM2-mercaptoethanol at 4C. The dialyzed proteins were then centrifuged for 20min
at 35,000 g at 4C and the protein concentration was determined by absorbance measurements at 280 nm wavelength using calcu-
lated molar extinction coefficients. All the ITC experiments were carried out at 25C. The binding reactions were performed using
5-15 mMmacrodomain and 50-150 mM ligand in the syringe. For the ALC1 macrodomain–ATPase interaction studies, all the exper-
iments were carried out using 10 mM ATPase (cell) and 120 mM of ALC1 macrodomain (syringe). For the competition assay, 4.5 mM
ALC1 macrodomain was incubated with 2-fold molar excess of tri-ADP ribose (9 mM) at room temperature and then loaded into the
cell. The same molar concentration of tri-ADP ribose was added into the ligand-containing solution consisting of 45 mM of ATPase.
PEAQ-ITC Analysis Software (Malvern) was used for data analysis. GraphPad Prism software was used to plot the data. Adenosine
50-diphosphoribose was bought from Sigma (A0752). Di- and tri-ADP ribose were synthetized and purified (Kistemaker et al., 2015).
Plasmids for cellular assays
The mammalian expression constructs of N-terminally fluorescent tagged bait and prey were generated by cloning of the relevant
DNA sequences in the fluorescently tagged LacR containing mammalian expression vectors and without LacR containing mamma-
lian expression vectors, respectively (Table S3). All plasmids were generated following usual cloning procedure and were validated
by Sanger sequencing.
Cell culture and transfections
For all the F2H assays, human U2OS cells harboring the stably integrated lacO (256x) array was used (Soutoglou and Misteli, 2008).
Cells were cultured in DMEM (Sigma) supplemented with 10% (v/v) FBS (GIBCO), 1 mM sodium pyruvate (Sigma), 2 mM L-glutamine
(Sigma), 100 U ml-1 penicillin, 100 mg ml-1 streptomycin (Sigma) and 200 mg ml-1 hygromycin B (Sigma) with 5% CO2 at 37C in a
humidified environment.
Microscopy experiments
All microscopy experiments were performed in borosilicate 8-well Lab-Teks (Thermo Scientific). A Zeiss AxioObserver Z1 confocal
spinning diskmicroscopewas used for imaging. Imageswere acquiredwith an AxioCamHRmCCD /EMCCD/cCMOS camera (Zeiss)
using Zeiss C-Apochromat 40x/1.2 water immersion and 63x/oil immersion objective lenses. Cells were imaged 24 hr post-
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UV-laser micro-irradiation assays
Live cells were imaged on a AxioObserver Z1 confocal spinning-disk microscope equipped with an AxioCam HRm CCD camera
(Zeiss) through a Zeiss 40x/water objective lens. For laser micro-irradiation, a 355-nm-wavelength diode-pumped solid-state pulsed
laser (DPSL-355/14, Rapp OptoElectronics) was used. DNA damage was induced by focusing the 355 nm pulsed laser in the nucleus
either as a small circle or as a line through the entire diameter of the nucleus. Cells were imaged at room temperature in a CO2
independent medium (1x; GIBCO).
PARP1 inhibitor treatment and H2O2 treatments
For F2H and laser micro-irradiation experiments, cells were treated with 30 mM of the PARP1 inhibitor AG14361 (Selleck Chemicals)
for at least 60min, for the LacO array de-compaction experiments with PARP1 inhibitor cells were treated with the inhibitor for at least
24 hr before imaging (at the time of transfection itself). Cells were imaged immediately after H2O2 treatment, which was diluted to
1:2000 from stock H2O2 solution (30% v/v) in the imaging medium.
Fluorescence two-hybrid (F2H) assay
F2H assays were performed as previously described (Bowman et al., 2016; Czarna et al., 2013). Briefly, assays were performed in
borosilicate 8-well Lab-Teks (Thermo Scientific). The fluorescently tagged bait and prey proteins were transiently co-transfected, us-
ing Xfect reagent (Clontech) according to the manufacturer’s recommendations. Cells were imaged at 25C in a CO2-independent
imaging medium (GIBCO) supplemented with 10% (v/v) FBS (GIBCO), 1 mM Sodium pyruvate (Sigma), 2 mM L-glutamine (Sigma),
100 U ml-1 penicillin, 100 mg ml-1 streptomycin (Sigma). Image analysis was manually performed with FIJI (ImageJ) image analysis
software (Schindelin et al., 2012). Briefly, the average fluorescence intensity of the prey (mEGFP fusion) over the LacO array was
divided by the average fluorescence intensity in the nucleoplasm to get the enrichment ratio. The fluorescent bait spot was identified
by the localization of anchored bait protein (Fluorescent LacI fusion) on the LacO array. Only the cells that show a clearly discernible
Lac repressor spot in the nuclei were chosen for analysis. The fluorescence intensity of the prey on the array and outside the array
(nucleoplasm) was calculated, background subtracted and plotted as the ratio of the two (as enrichment ratio).
Co-immunoprecipitation assays
To test whether ALC1 oligomerizes in vivo, EGFP- and mCherry-tagged ALC1, EGFP-SPT16 and SSRP1-mCherry (positive control)
or EGFP and mCherry-ALC1 (negative control) were expressed in U2OS cells for 24 hr and treated with 30 mM AG14361 PARP In-
hibitor (Selleckchem) for 1 hr before lysis. GFP-tagged proteins were immunoprecipitated using GFP-trap (Chromotek) following
manufacturer’s instructions. AG14361 (30 mM) was further supplied during all incubation steps. Interaction between GFP- and
mCherry-tagged proteins was examined by western blotting using GFP- (Eurogentec) and mCherry-antibodies (Novus Bio,
NBP2-25157), respectively.
LacO array remodelling assays
The LacO array de-compaction assays was performed in the same way as the F2H assay, with the only difference in the analysis of
the results, wherein the area covered by the Lac repressor fusion protein on the LacO arraywasmeasured and normalized by the total
area of the same nuclei, which was then plotted as % Nucleus area. Only the cells, which show a clearly discernible Lac Repressor
decompacted spot in the nuclei, were chosen for analysis.
V5-Macrodomain pull-down assays
For V5-Macrodomain pull-down assays V5-tagged Macrodomain (615-876) of ALC1 was used as bait on the anti-V5 Agarose affinity
gel beads in 1x PBS buffer. Other indicated proteins (like ATPase domain, PARP1) and ligands (DNA, NAD+, ADP-ribose ligands,
PolyA-DNA, PARP1 inhibitor) were added to the pre-incubated V5-macrodomain bound beads as indicted and the complex was
incubated on room temperature for 30min before centrifugation followed by 3washes in PBS andwas finally boiled in Laemmli buffer
before running on a 4%–12% gradient SDS-PAGE gel.
Fluorescence correlation spectroscopy (FCS)
FCS experiments were performed on a Leica SP8 confocal microscope equipped with a Plan APO 63x/1.2 N.A. water immersion
objective. GFP fluorescence was excited with a 488 nm laser and emission selected by a bandpass filter at 500-550 nm. Laser power
used for FCS measurements was adjusted to minimize photobleaching. Pinhole was set to one Airy unit. Single photons were
detected and counted using a single photon avalanche diode and a PicoHarp module from PicoQuant. To estimate the residence
time of GFP-tagged constructs in the focal volume, autocorrelation curves were fitted with a one-species model assuming pure diffu-
sion and neglecting the contribution of the photo-physics of GFP using the Fluctuation Analyzer 4G software (Wachsmuth
et al., 2015).
Thermal shift assays
Fluorescence-based thermal shift assays were conducted on an Applied Biosystems 7500 fast real-time PCR system. 2 mM protein
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heated in 25mM Na-PO4 (pH 7.0), 0.25M NaCl and 1mM DTT from 5
C to 95C at a ramp rate of 1%. The assays were conducted in
MicroAmp Fast 96-well reaction plates sealed with MicroAmp Optical Adhesive Film (Applied Biosystems). The fluorescence mea-
surements at 554nm were normalized to the lowest value before the transition and the maximum fluorescence.
Chromatin remodeler ATPase assays
The ALC1 catalyzed ATP hydrolysis was performed in 384-well using a malachite green assay (Greiner Bio One). For this, 1mM
recombinant (near) full length ALC1 protein (residues 31-878) or the constitutively active ATPase fragment (residues 31-674) were
pre-incubated for 10 min at RT with 1 mM dsDNA (75 bp with 4 nt overhangs on both ends; see Key Resources Table for their
sequence) in 25 mM Bis-Tris pH 7.0, 0.15 M NaCl, 1 mM MgCl2, 50 mM ZnCl2, 1 mM DTT and 5% (w/v) glycerol in the absence or
presence of ligand (5 mM tri-ADP-ribose or 15mM monomeric ADP-ribose). In case of the constitutively active ATPase fragment,
the reactions were additionally performed in the absence or presence of 2.5mM ALC1 macrodomain (residues 636-878). The reac-
tions were started by the addition of 1 mL 1 mM ATP, giving a final volume of 10 mL. After 5 min at RT, the reactions were stopped
by the addition of 20 mL Biomol Green (Enzo Life Sciences), and the color was allowed to develop for 15 min. The absorbance of
the resulting phosphomolybdate complex was read at 640 nm on a Tecan Infinite M1000 Pro microplate reader.
Analytical size exclusion chromatography (aSEC)
Globular proteins of known molecular weight from the Gel Filtration Calibration kit (GE Healthcare) and a Gel Filtration Standard
(BioRad) were used to calibrate a Superdex 200 Increase 10/300 column (GE Healthcare). Blue dextran was used to determine
the column void volume. Protein elution volumes were measured by monitoring the absorption at 280 nm. The elution volumes
were used to calculate the partition coefficient (Kav) with the formula Kav = (Ve  V0)/(Vt V0) where Ve is the elution volume, V0 is
the void volume, and Vt is the total volume of the column. The apparent molecular weight was then derived from the inverse logarithm
of the partition coefficient. All aSEC experiments were performed in 25 mM Na-PO4 (pH 7.0), 0.25 M NaCl and 1 mM DTT.
QUANTIFICATION AND STATISTICAL ANALYSIS
For in vitro ATPase and Thermofluor assays
The experiments were performed three times as technical triplicates. The blank-subtracted values were normalized to the respective
mean ATPase activity in the absence of the macrodomain or to the mean activity of the full-length protein. Blank values were deter-
mined by measuring the absorbance under identical conditions without ATP. All Thermofluor experiments were performed multiple
times as technical replicates.
For the F2H and lacO array assays
The Wilcoxon matched-pairs signed rank test was used since normal distribution could not be assumed to determine the statistical
significance in F2H and LacO decompaction assays (biological replicates nR 2). The column in the graph represents theMean, error
bar represents the SEM and number of cells isR 20. Actual p values are indicated in the figures. GraphPad Prism software was used
to plot and analyze the data.
For HDX-MS measurements
For statistical analysis of the HDX-MS data, the standard deviation of measured deuterium content in each peptide based on tech-
nical replicates (n = 2 or n = 3) and using all relevant charge states. A significance threshold for differences in HDX between individual
protein states was set to 0.52 D, corresponding to the 98.75% confidence interval (CI) calculated using technical replicates (n = 3)
data from a single time-point for full-length ALC1 in the presence or absence of tri-ADP-ribose. The CI was calculated according to:
CI= x ± t  sffiffiffi
n
p
where x is the average difference in deuterium content assuming a zero-centered distribution (x = 0), t is 8.86 for the 98.75%CI with
2 degrees of freedom, s is the average propagated standard deviation of differences in deuterium content for all peptide segments,
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